Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today ...
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK ...
STARLIMS, a global leader in Laboratory Information Management Systems (LIMS) and informatics solutions, today announced ...
PharmaJet will deliver two presentations on October 27 focusing on current and future applications of their needle-free ...
This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and ...
Chemify raises > US $50 million in Series B funding to globalise its AI-driven digital chemistry and molecule-manufacturing ...
Named after Dr. James Robert Cade, the lead inventor of Gatorade, the Cade Prize for Inventivity celebrates early-stage ...
New tool helps sponsors measure, manage and minimize the environmental impact of researchWILMINGTON, N.C.--(BUSINESS ...
Black Book survey reveals just 1 in 4 hospitals can fully exchange patient data across national boundaries in Q4 2025 VIENNA, ...
IFF and BASF Announce Strategic Collaboration to Drive Next-Generation Enzyme and Polymer Innovation
IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announced a strategic ...
Challenges and New Momentumchina’s pharmaceutical innovation goes global challenges and new momentumIn the first five months ...
Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to License Global Rights to an Early-Stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback